Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q36452241

about

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia Asparaginase pharmacokinetics and implications of therapeutic drug monitoring How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia Osteonecrosis in children with acute lymphoblastic leukemia Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase Effect of premedications in a murine model of asparaginase hypersensitivity Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.Inherited genetic variation in childhood acute lymphoblastic leukemia.Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).High-throughput asparaginase activity assay in serum of children with leukemia A 50-year journey to cure childhood acute lymphoblastic leukemia L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.Asparaginase-associated pancreatitis in children.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.Asparaginase pharmacology: challenges still to be faced.Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.Reactions related to asparaginase infusion in a 10-year retrospective cohort.A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy.Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.

P2860

Q26738640-8D3C4835-E6DC-45CF-A55B-775AEC2B1067 Q26784116-B8B73B22-A2DF-43EE-B901-134C87E89FDE Q26825970-EA5B9FCF-975E-4CCE-B9AE-A959472D978C Q27026476-E2016E01-AC97-40C9-98FB-D08655E7C9CA Q27026952-6E2BA122-2215-4946-92C4-96360BA53CA8 Q28066799-4B1A00B8-7001-4BE5-B2B1-4207EEC22DD7 Q30244110-ED34FA62-D19F-4C77-BE39-1671933D8959 Q30371340-CD06757F-786F-424D-B41E-0BFBAB60127F Q33557148-45A00DB4-C583-48F6-8979-CD3B5A95991B Q34064049-58B163F7-5F4B-4652-A480-EB3F3D4CE333 Q35156439-AB11143C-C0B6-4701-AD91-D9CBB374625C Q35740019-E303B19F-2E93-49D5-950B-79DAC4DF0769 Q35784497-2CADF80F-E692-46D3-A3D7-313534B82703 Q35820373-999739AA-A2CC-4C53-AA91-F45428CD8877 Q35954058-98B954C2-B4EF-409D-AA12-955BA8362F00 Q36143232-68270C09-841A-471C-A506-7F782CCA1ED3 Q36163029-7FFE2CE3-182C-42A1-B42B-671D6EAD552E Q36678136-052BC259-7C8D-42C3-BB5D-400E85C38733 Q36762608-CDEB0132-E225-41BC-8123-0F10B19A8926 Q36895136-998AFF81-8F70-41DC-A70F-CC81EED217E0 Q37063860-E6F005CF-4313-4E2D-BA92-9D039FAE0EE5 Q37166753-B41FBC29-4135-4809-87E2-741355038B61 Q37379199-2DA6DA2F-BDBF-42E1-9FE9-8481ECB99694 Q38036389-3C5A894F-4824-44BD-A878-E6F22F2696BD Q38079075-4B303BB8-FC58-4C5D-8D0D-2B2F3C0B8642 Q38132699-753E486A-16B3-417B-8A07-58678771E471 Q38821455-23F39EDF-D677-4A1B-90D2-798ECA138842 Q38880102-528F56EF-8401-4AF8-85D4-E95BAFF5B05D Q38933372-5DE811ED-2901-428D-B25D-3E4DA349DBBA Q38941947-E7B5AA01-FF68-48A4-B8DC-B2CE36A68446 Q39135887-AC30F590-5F5C-42A4-BE54-AC361EDAE349 Q39194553-7BC604C5-6938-4116-9757-EC50FD207480 Q40243523-498D9D5E-BD7E-467E-9D4D-6C28AAF26171 Q41491082-5E50CF9D-9E4E-4ABC-AC7C-A8DBBA91770B Q45072276-EE680687-7F98-4A42-B949-7BAEB33BAC9E Q47133515-74A6ABD6-1187-4B39-A457-0CE8BFAB40BF Q47608786-AFA7CDEB-33A3-48CA-8CE4-1C53C2CDA0C1 Q48203946-E7F0FCE4-523A-4F37-9321-245F4D58F45A Q51071633-3E4D15A0-C659-4A77-92E3-1311AEF5442A Q51664868-8B87EB27-F90E-483B-981D-AE9AF9A92D8C

P2860

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q36452241

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@ast

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@en

type

label

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@ast

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@en

prefLabel

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@ast

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@en

P1433

Q36452241-BC431547-D4DE-41D5-B133-0566620F7F10

P1476

Q36452241-CC7D4060-CB42-4796-9FBF-55BDEC49D9D6

P2093

Q36452241-0DA07B80-93CB-4B92-935A-77B4108B5DED

Q36452241-15BE09D1-160C-4236-9AB6-8E632C499FFF

Q36452241-162A2900-C971-42C0-8FE9-7DFEE479825E

Q36452241-2ABACDCD-311D-4253-954F-0A332BBD078F

Q36452241-37D2996D-1774-4D86-B8C9-20D29F12B98D

Q36452241-3843BB76-46FE-4E8A-81C1-70C84D225661

Q36452241-5096A718-F6C8-4102-A2E8-6DF31C29E003

Q36452241-73D1AD66-895F-438A-9800-E000B254C71C

Q36452241-801AC67C-563F-4856-8C01-B92976380263

Q36452241-854001CD-46AE-4B0C-B07B-E528F61ED710

P2860

Q36452241-0182BE0F-847D-46CD-AB25-9DFEC60CF918

Q36452241-11A4A249-33A3-4DC3-9032-AFD97A635F53

Q36452241-16606936-F8CE-4EDB-A837-AE848A9C694B

Q36452241-1B7B1E83-369A-4453-9626-D55083880539

Q36452241-1BE7D7B1-8C28-4555-9175-2AF01388601F

Q36452241-1D0FC668-BF60-48E3-888F-B501E6F10DED

Q36452241-220A73E6-C9EF-4D8B-A414-6A3C592E439A

Q36452241-33C33045-BA6C-4ED5-8F05-560F3076D8A2

Q36452241-362D0C82-E7CC-4385-AA9A-0F9FC0E69C18

Q36452241-4119DB64-00CB-4464-9FEB-B1620BA93089

P2888

Q36452241-659DD882-04C5-41BD-98D8-2CFDF515AEAB

P304

Q36452241-E713F901-1C8F-42CB-9297-D63937108F14

P31

Q36452241-3BB38637-5390-4CE6-9246-96BBA980747D

P356

Q36452241-29DE29A8-31A9-4592-92DF-226A30326F83

P433

Q36452241-783D62B8-A20E-4519-97DA-AC22AA0827BB

P478

Q36452241-E8500C5A-ED37-464C-8C74-15E00D4BBC35

P577

Q36452241-E2FE10CD-E571-4C6B-AE74-53AEDBB6CE44

P5875

Q36452241-69887488-B182-4582-A38E-07EA79430854

P698

Q36452241-13771D23-0757-481E-9BCA-E900291DB6AB

P921

Q36452241-101ADFB3-2BEB-4FF9-BE41-FA76E013D7B2

P932

Q36452241-B6A55654-5966-496A-8C32-F95831326C70

P356

P1433

P1476

Clinical utility and implicati ...... acute lymphoblastic leukemia.

@en

P2093

C A Fernandez

http://www.w3.org/2001/XMLSchema#string

C Cheng

http://www.w3.org/2001/XMLSchema#string

C Liu

http://www.w3.org/2001/XMLSchema#string

C-H Pui

http://www.w3.org/2001/XMLSchema#string

D Pei

http://www.w3.org/2001/XMLSchema#string

J C Panetta

http://www.w3.org/2001/XMLSchema#string

J D Kawedia

http://www.w3.org/2001/XMLSchema#string

J T Sandlund

http://www.w3.org/2001/XMLSchema#string

K R Crews

http://www.w3.org/2001/XMLSchema#string

M V Relling

http://www.w3.org/2001/XMLSchema#string

P2860

Treating childhood acute lymphoblastic leukemia without cranial irradiation

Immunological responses to L-asparaginase.

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.

D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review.

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.

Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy.

P2888

P304

2303-2309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.102

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223965823

http://www.w3.org/2001/XMLSchema#string

P698

22484422

http://www.w3.org/2001/XMLSchema#string

P921

P932

3516853

http://www.w3.org/2001/XMLSchema#string